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Management of Animal Botulism Outbreaks:
From Clinical Suspicion to Practical Countermeasures
to Prevent or Minimize Outbreaks
Fabrizio Anniballi, Alfonsina Fiore, Charlotta Lo¨fstro¨m, Hanna Skarin, Bruna Auricchio, Ce´dric Woudstra,
Luca Bano, Bo Segerman, Miriam Koene, Viveca Ba˚verud, Trine Hansen, Patrick Fach, Annica Tevell A˚berg,
Mikael Hedeland, Eva Olsson Engvall, and Dario De Medici
Botulism is a severe neuroparalytic disease that affects humans, all warm-blooded animals, and some fishes. The disease is caused
by exposure to toxins produced by Clostridium botulinum and other botulinum toxin–producing clostridia. Botulism in animals
represents a severe environmental and economic concern because of its high mortality rate. Moreover, meat or other products
from affected animals entering the food chain may result in a public health problem. To this end, early diagnosis is crucial to
define and apply appropriate veterinary public health measures. Clinical diagnosis is based on clinical findings eliminating other
causes of neuromuscular disorders and on the absence of internal lesions observed during postmortem examination. Since clinical
signs alone are often insufficient to make a definitive diagnosis, laboratory confirmation is required. Botulinum antitoxin
administration and supportive therapies are used to treat sick animals. Once the diagnosis has been made, euthanasia is frequently
advisable. Vaccine administration is subject to health authorities’ permission, and it is restricted to a small number of animal
species. Several measures can be adopted to prevent or minimize outbreaks. In this article we outline all phases of management of
animal botulism outbreaks occurring in wet wild birds, poultry, cattle, horses, and fur farm animals.
Botulism is a severe neuroparalytic disease thataffects humans, all warm-blooded animals, and some
fishes. The illness is caused by exposure to botulinum
neurotoxins (BoNTs), which are produced by anaerobic,
spore-forming, ubiquitous microorganisms belonging to
the genus Clostridium, referred to as BoNT-producing
clostridia. BoNTs act on nerve endings blocking acetyl-
choline release. Their potency depends on 2 factors: their
enzymatic activity and their selective affinity for binding
neurons.1,2 Human disease does not differ fundamentally
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in clinical features, diagnosis, supportive laboratory testing,
management, or therapeutic measures from that seen in
veterinary practice, but the rarity of human botulism con-
trasts with the frequent occurrence of animal botulism.3,4
On a worldwide basis, avian botulism probably represents
the most important disease of migratory birds. More than a
million deaths have been reported in relatively localized
outbreaks in a single year, and outbreaks with losses of
50,000 birds or more are relatively common.5
Botulism in animals represents a serious environmental
and economic concern because of the high mortality observed
during the outbreaks. BoNTs and BoNT-producing clos-
tridia represent an additional concern because of their po-
tential use as biological weapons.6,7 A bioterrorist attack
directed at a livestock population by means of viruses, mi-
croorganisms, or toxins could instill fear among the popula-
tion and cause major economic consequences; thus, livestock
agroterrorism has caught the attention of government pol-
icymakers in most countries.8 It may be difficult to attribute
an animal disease outbreak to a biological attack. In fact,
unlike bioterrorism attacks directed toward humans, bio-
terrorism attacks on livestock or poultry would have fewer
indications that could be used to distinguish them from
natural outbreaks.8 The countermeasures to prevent a possi-
ble agroterrorism attack include sharing information among
government agencies, improving veterinary and public health
awareness, and supporting research to identify new, more
efficient and rapid methods to combat these threats.8
This article outlines phases of management of animal
botulism outbreaks from clinical suspicion to practical
countermeasures to prevent or minimize outbreaks occurring
in waterfowl, poultry, cattle, horses, and fur farm animals, in
the framework of the activities promoted by the European
research project AniBioThreat (www.anibiothreat.com).
BoNT-Producing Clostridia
and Their Toxins
The species Clostridium botulinum and some strains of
Clostridium baratii and Clostridium butyricum are currently
classified as BoNT-producing clostridia. On the basis of
their genotypic, phenotypic, and biochemical characteris-
tics, these strains are divided into 6 groups: C. botulinum
(groups I-IV), C. butyricum, and C. baratii. Groups I and
II, C. butyricum, and C. baratii are mainly associated with
human botulism, whereas group III organisms are mainly
responsible for animal botulism.1,2 Group IV organisms,
also known as Clostridium argentinense, are associated with
wound botulism.9 On the basis of the BoNTs produced,
these strains can additionally be classified in 7 groups, from
A to G.1,2 Group I and II organisms are capable of pro-
ducing type A, B, E, and F toxins; group III organisms can
produce type C, D, and their mosaic C/D and D/C
toxins.10-12 Group IV, C. butyricum, and C. baratii produce
type G, E, and F toxins, respectively. Some strains are also
capable of producing 2 toxins simultaneously or may carry
a second silent nonexpressed gene.13,14
C. botulinum strains play a vital role in the natural car-
bon recycling process, growing in decaying organic matter
(eg, animal carcasses) and producing high levels of BoNTs.
High protein substrates are essential because C. botulinum
lacks the ability to synthesize certain essential amino acids.
Also, pH and salinity in the sediments together with tem-
perature play a crucial role for growth and toxin produc-
tion, with an optimum growth temperature between 25C
and 42C.4,5,15 Type D strains can produce toxin in carrion
at a temperature as low as 9C, whereas a type C strain
failed almost completely to do it at 16C.16
BoNT-producing clostridia secrete the toxins during
their vegetative growth as inactive single-chain polypeptides
that subsequently are activated by bacterial or tissue pro-
tease. In nature BoNTs are found as progenitor toxins
containing the neurotoxin and nontoxic associated pro-
teins, probably responsible for protecting the neurotoxin
from environmental factors.17 Genes encoding BoNTs can
be located on the chromosome or on extrachromosomal
elements, such as plasmids or bacteriophages.18-20 Specifi-
cally, toxin genes for group III organisms are carried by
bacteriophages that exert an unstable lysogenic cycle. Mo-
lecular and genomic analysis of the bacteriophage genome
revealed that this phage exists as a circular plasmid pro-
phage in the lysogenic state, and it does not integrate into
the host chromosome.21
The sensitivity to BoNTs seems to be widely variable
among the different animal species. Cattle botulism is most
frequently caused by type D or D/C toxin, followed by type
C toxin, although type A, B, and C/D toxin types have also
been reported. In wild birds, the most common toxin iso-
lated is type C and for fish-eating waterfowl type E. In
contrast, in poultry the most common toxins are type C
and C/D, although type A has been reported. The mosaic
toxin type C/D seems to be more lethal to chickens than
type C toxin.10 In addition, birds may harbor type D C.
botulinum strains in their gut without showing symp-
toms.22 Equine botulism is caused by type B, C, and A
toxins.22-25 Fur farm animals (eg, fox, ferret, mink) seem to
be susceptible to type C and type C/D toxins, but rare
outbreaks due to type A and E toxins have also been
reported.22,26,27
Pathogenesis and Pathophysiology
BoNT is the etiological agent of human and animal bot-
ulism. As extensively reported elsewhere, the BoNT
mechanism of action consists of the following steps: The
active toxin is absorbed in the small intestine by binding to
the receptors on the apical surface of gut epithelial cells. It is
then released into the general circulation, reaching all pe-
ripheral cholinergic nerve endings. In these sites, the toxin
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binds to specific receptors and is internalized into the cy-
tosol of the nerve terminus, where it blocks the release of
acetylcholine, producing the characteristic paralysis.28,29
For animal botulism, as well as for human botulism, the
primary contamination route is the ingestion of preformed
toxins in foods or feeds. Raw material, such as grass, hay,
rotting vegetation, and slaughterhouse waste, as well as
decay of vertebrate carcasses, invertebrates, and sewage may
support BoNT-producing clostridia growth and toxin
production. Animals may directly ingest decaying organic
matter containing toxin, or they may ingest toxins through
the consumption of zooplankton or invertebrates, such as
larvae, that have consumed toxic material.
Fly larvae and other invertebrates are unaffected by the
toxin, but feeding on toxigenic carcasses may concentrate
toxin. Ingestion of a single toxigenic maggot could be le-
thal. This is described as the carcass-maggot cycle of bot-
ulism.30 There is also some evidence that exposure to
poultry litter as feed or bedding may constitute a risk factor
in the occurrence of cattle botulism.31-33 Typically, type C
and D toxins are associated with carrion of birds or small
animals that have contaminated water, feed, or the envi-
ronment, while noncarrion-associated botulism is caused
by type A and B toxins.4,33-35
A second form of animal botulism is associated with the
absorption of BoNTs produced in vivo in the intestinal
tract. This form of botulism, seen in chickens and horses,
can be categorized as a toxicoinfection.36,37 Bo¨hnel and
colleagues describe a toxicoinfection in cattle, referred to as
‘‘visceral botulism.’’38 This form of animal botulism is
hypothesized to occur when C. botulinum colonizes the
lower section of the intestine. BoNT is formed and partially
absorbed by mucous membrane, and the rest is excreted
with the feces. Excretion of feces containing BoNTs by
animals that do not show any clinical symptoms of acute
paralysis may demonstrate the production of toxins in the
lower sections of intestines where only a low amount is
absorbed, in contrast to the proximal parts of the intestinal
tract in which toxins are highly absorbed.38
A third form of animal botulism is caused by the ger-
mination and production of BoNTs by C. botulinum spores
in infected wounds.3,37,39 The last 2 forms are often re-
ferred to as toxicoinfectious form botulism.
Clinical Manifestations
All forms of botulism are characterized by a progressive,
symmetrical, flaccid paralysis that often starts in the hind-
quarters with weakness, muscle tremors, stumbling, and re-
cumbency and often results in death. The speed of progression
is variable, resulting in peracute, acute, and chronic forms of
the disease. Some cases may present as sudden deaths. De-
pending on the amount of ingested toxin, initial signs may be
subtle or overt. Generally, the clinical signs appear from 24
hours up to 17 days. In monogastric animals, the incubation
period of foodborne botulism is usually shorter than for ru-
minants, in which clinical signs may be absent for over a week.
For toxicoinfectious forms, the incubation period is usually
longer, and an indicative period of 4 to 14 days has been
reported in the literature.3,22,40
Signs of the intoxication include reluctance of the ani-
mals to rise; the lying posture may be abnormal, and, on
rising, the gait may be stilted and the hind limbs splayed
and ataxic. Weakness then progresses to the forequarters,
head, and neck. An abnormal posture of the head may be
evident. Apparent lethargy, depression, and dullness of
expression may be the results of loss of tone around the eyes
and mouth. The eyes may appear closed, the pupils dilated,
and pupillary reflexes sluggish.3
Clinical Manifestations in Birds
In birds, the flaccid paralysis progresses cranially from the
legs, to include wings, neck, and eyelids. Initially, affected
birds are unable to sustain flight or show uncoordinated
flight and may be found sitting and reluctant to move. They
seem lame, and the wings may droop when paralyzed.
Paralysis of the inner eyelid or nictitating membrane and
neck muscles follows, resulting in the inability to hold the
head erect. Birds may also appear lateral or ventral re-
cumbent and comatose or dead.3,40,41 Recumbent birds
intermittently stand and walk a few steps. Often they
cannot stand up completely and even walk on their tar-
sometatarsi. More severely affected water birds are unable
to walk and drag themselves forward using their wings and
beak.5,40,41 Broilers generally appear ruffled and often show
defeathered areas on the back. Affected chickens may have
soiled vents caused by diarrhea.40,42,43
Clinical Manifestations in Cattle
Cattle in the early stage of the disease appear listless, re-
luctant to move, and stiff. Constipation and signs of colic
may be present at this stage. Weakness in the hind limbs
results in difficulty rising, and affected cattle therefore often
appear recumbent. Dysphagia is present in most, but not
all, cases of botulism in cattle. Decreased masseter tone,
decreased tongue strength, and pharyngeal paresis or pa-
ralysis may contribute to dysphagia, each in variable degree.
At this stage the animals remain bright and alert and usually
are able to eat the grass around them and drink water from a
bucket. As the paralysis progresses, they may become un-
able to eat and drink, they may be laterally recumbent with
terminal abdominal breathing, and the tongue may lose
reaction strength and become completely paralyzed. Other
clinical signs include photophobia, sluggish rumen move-
ments, reduced anal tone, and tail paralysis.34 Atypical
clinical presentation can appear in cattle because of the
ingestion of BoNT/B, including diarrhea, profuse saliva-
tion, regurgitation, and vomiting.40
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Clinical Manifestations in Horses
The clinical signs in horses are similar to those in cattle. The
main signs in adult horses are generalized muscle weakness
and dysphagia; decreased tail, eyelid, and tongue tone;
mydriasis; and prolonged pupillary light reflex, frequently
followed by recumbency, respiratory failure, and death.
Further signs such us anorexia, weight loss, colic, hyper-
salivation, and tachycardia are common.22-25 Horses with
type C botulism may have more prominent mydriasis,
more labored breathing, or less dysphagia than horses with
type A or B botulism.23
In foals, the ‘‘shaker foal syndrome’’ appears to be similar
to infant botulism. The initial presenting sign is often the
onset of muscle tremors leading to recumbency. Dysphagia;
constipation; reduced eyelid, tongue, and tail tone; my-
driasis; sluggish pupillary light reflexes; and frequent uri-
nation may also be seen.25
Clinical Manifestations
in Fur Farm Animals
In fur farm animals, the most typical clinical picture in-
cludes the same clinical signs as those in large domestic
animals. Paralysis of the hind legs, total paralysis, and re-
cumbency are common. Foxes with milder symptoms often
take a sitting position, dragging the rear part of their
bodies.26 In ferrets, clinical signs include weakness, ataxia,
ascending paralysis, blepharospasm, photophobia, and
urinary incontinence, with death resulting from respiratory
failure. The progression of botulism can be very fast in fur
animals. In some cases, animals that have appeared well
have died only 2 or 3 hours later.44
Diagnosis
Clinical Signs
Clinical signs of animal botulism are often strongly indic-
ative but not specific. A presumptive diagnosis is based on a
combination of signs observed in sick animals, the duration
of the outbreak, and the postmortem findings and by ruling
out other differential diagnoses.
Avian botulism most often afflicts waterfowl in the sea-
son when they are flightless because of wing molt. It is
therefore essential to distinguish between birds in molt and
birds with early stages of botulism, since the behavior of
these birds may be similar. Molting birds are very difficult
to catch, whereas birds that are suffering from botulism can
easily be captured when they lose the ability to dive to
escape pursuit. Birds at this level of intoxication still have a
high probability of surviving if they are properly treated.
During outbreaks it is common to find healthy, sick, and
dead animals in the same area.5
In cattle, clinical signs (especially flaccid paralysis), the
epidemiology of the outbreak, the clinical chemistry (es-
pecially hyperglycemia, although this can occur in any cow
with a severe life-threatening disease), and neutrophilia
support the diagnosis.28,38 Differential diagnosis includes
hypocalcemia, hypomagnesemia, carbohydrate overload,
and toxicosis, including from mycotoxin, lead, nitrate, or-
ganophosphate, atropine or atropine-like alkaloid, tick
paralysis, and paralytic rabies.3,34,45
In horses, weakness, decreased eyelid tone, decreased or
absent tongue tone, decreased tail and anal tone, sluggish
pupillary light reflex, and occasional episodes of slow and
uncoordinated padding support the diagnosis. Differential
diagnosis includes toxic plant poisoning, organophosphate
intoxication, equine viral encephalitis, central nervous sys-
tem trauma, equine protozoal myeloencephalitis, aberrant
larval migration, and hyperammonemia.35 In horses that
feed in a group, the dominant horse eats first and is therefore
usually the first one to develop clinical signs and shows most
rapid progression of the neurotoxic syndrome.35
Postmortem Examinations
Postmortem examination is usually unremarkable, although
in more protracted cases, secondary pathologies may be
present. Negative postmortem results can be used as a di-
agnostic tool per exclusionem.22 Diffuse intestinal hemor-
rhage may be observed on postmortem examination, as
some strains of C. botulinum type C and D also produce an
enterotoxin, but these changes are not consistent or suffi-
ciently specific to confirm a diagnosis. Nevertheless, a full
necropsy should be carried out on as many cases as possible
to help rule out other conditions. In particular, stomach
contents should be examined for evidence of suspicious
material (eg, decayed carcass material, bones, maggots).34,41
Avian botulism should be suspected when maggots are
found as part of the ingesta of gizzard contents of dead
birds; however, such findings are rare.5 A presumptive di-
agnosis is often based on a combination of signs observed in
sick animals.
Specific neurophysiological studies such as repetitive
nerve stimulations have been particularly useful as a diag-
nostic aid for neuromuscular disease. In large animal neu-
rology, the use of electrodiagnostics has been limited
compared with other species. Aleman and colleagues sum-
marized neurophysiological studies conducted on foals.46
In horses, edema of the head and neck may be a pro-
minent, although inconsistently observed, necropsy finding
associated with botulism. In some cases, edema might be
attributable to simple hydrostatic mechanisms, secondary
to the unnaturally prolonged static posture.35
Laboratory Confirmation
Laboratory confirmation can be done by demonstrating: (1)
BoNTs in serum, gastrointestinal content, liver, and
wound; (2) BoNT-producing clostridia in gastrointestinal
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content, liver, and wound; (3) BoNTs or BoNT-producing
clostridia in feed or the close environment of the sick ani-
mal; or (4) an antibody response in an animal with
symptoms of botulism.22,47 Demonstration of BoNTs in
serum, feed material, or intestinal content by the mouse
bioassay remains the gold standard for laboratory confir-
mation of botulism. However, a negative mouse bioassay
does not exclude the botulism diagnosis, because the toxin
may be present at a level below the limit of detection or may
have been biodegraded by microbes in the intestinal tract of
the animals.48 Since BoNT-producing clostridia are not a
normal inhabitant of the gut, but are present in the ali-
mentary tract of animals that have recently ingested con-
taminated material, demonstration of spores in the
gastrointestinal contents or tissue of animals with symp-
toms is indicative of botulism. This is supported by the
clinical diagnosis, as well as demonstration of neutralizing
antibodies, and may allow a retrospective diagnosis in re-
covered animals. Demonstration of BoNT-producing
clostridia or BoNTs in feed given to animals that show
symptoms of botulism may also help to identify the source
of contamination in order to prevent further cases.45
Because the use of in vivo assays is discouraged for ethical
reasons, a number of alternative methods have been de-
veloped, and some of them have been validated.47,49,50
Serum, ruminal or gastrointestinal content, fecal mate-
rial, tissue samples, and feed for laboratory investigation
should be collected as soon as possible after the onset of the
illness, or after death, to enable efficient detection of
C. botulinum and/or its toxins.
Treatment
When botulism is suspected, the first critical therapeutic
step is to give polyvalent antitoxin to affected animals.
Antitoxin treatment should be initiated as soon as possible,
because it is effective only against circulating toxin and not
when toxin is fixed at the neuromuscular junction. Anti-
biotic administration is indicated only when there is a
suspicion of inhalation pneumonia or wound infection.
Clostridiocidal drugs may lyse vegetative cells of BoNT-
producing clostridia, thereby increasing the amount of free
toxin in the intestinal tract. Aminoglycosides may poten-
tiate neuromuscular weakness and a nondepolarizing type
of neuromuscular block. Although antibiotic treatment is
discouraged, beta-lactams have been successfully used to
treat poultry affected by the toxicoinfection form of botu-
lism. Other therapies include supportive care (oral water
and electrolytes) and reduced physical activity.32,51,52 For
cattle, vaccination can be considered to be effective as a
therapeutic treatment in an outbreak situation.
Waterfowl can recover from botulism by being admin-
istered antitoxins or being provided fresh water and shade.
Treated birds should be maintained in pens that provide free
access to fresh water, shade, the opportunity for recovered
birds to fly out, and minimal disturbance.5 Once the diag-
nosis has been made, euthanasia is frequently advised to
avoid problems in maintaining the animals’ welfare.40,52
Prevention
Countermeasures to prevent or minimize feedborne botu-
lism are based on: (1) providing safe and high-quality feed
to farm animals; (2) properly storing animal feed; (3) in-
specting water sources for dying or dead small animals and
birds; (4) avoiding spreading poultry litter that contains
birds or dead animals on pastures; (5) avoiding using
poultry litter as bedding material; and (6) vaccinating an-
imals. These measures are described in more detail below.
Ensuring High-Quality Feed
for Farm Animals
Feed producers and suppliers should apply good
manufacturing practices and good agricultural practices to
ensure that fields are not spread with poultry litter con-
taining carcasses or others materials that may support the
growth of C. botulinum, as requested by EU legislation.53,54
Farmers should check the quality of the raw materials used
for silage and eliminate those presenting traces of con-
tamination with molds or that appear rotten or spoiled.
The current methods of mixing and distributing feeds, es-
pecially in cattle farms, mean that a small quantity of a
contaminant can easily be distributed. Farmers must take
precautions to avoid contamination of feed ingredients.55
Animal feed prepared without acidification is particu-
larly liable to growth and toxin production of BoNT-
producing clostridia. However, acidification does not neces-
sarily eliminate the risk of toxin formation in a carcass, unless
it is chopped into small pieces and the cells or spores present
in the carcass are exposed to the acid. Moreover, decom-
posing carcasses may contain large amounts of preformed
toxin that may be further spread to the feed on processing.56
Mitigating Environmental
Conditions
Preventing avian botulism outbreaks in waterbirds depends
on a thorough understanding of the interactions between
the agent, the host, and the environment. Because C. bot-
ulinum spores are ubiquitous in wetlands, attempts to re-
duce or eliminate the agent are not currently feasible.
However, some actions can be carried out to mitigate en-
vironmental conditions that increase the likelihood of
outbreaks. Wetland flooding and draining, pesticides, and
other agricultural pollutants, as well as anoxia of the wet-
land bottom, may kill or change aquatic life and provide
more substrates for the growth and toxin production of
BoNT-producing clostridia.5,41 Reduction of organic in-
puts into wetlands and elimination of factors that introduce
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large amounts of decaying matter, as well as a prompt re-
moval and proper disposal of vertebrate carcasses (appli-
cable also in farms), are efficient measures to remove
substrate, thus reducing growth and toxin production of
BoNT-producing clostridia.5,43,57,58
Vaccination
Preventing botulism can be efficiently achieved by vacci-
nation, which generates neutralizing antibodies against
BoNTs. Vaccine administration is subject to health au-
thorities’ permission and in the EU to Directive 2001/82/
EC of the European Parliament and of the Council.59 A list
of available vaccines is reported in Table 1.
In some countries in which botulism is endemic, cattle
have been routinely vaccinated against type C and type D
toxins. For example, in Israel the vaccination program for
cattle starts when they are 2 months old and consists of 2
doses 4 weeks apart followed by an annual booster. Vac-
cination of cattle with bivalent toxoids conferred consid-
erable immunity following exposure to BoNTs for
extended time periods.60
Immunization has been successfully adopted for broilers
grown on farms with recurrent cases of the disease and for
pheasants and ducks. In waterfowl, immunization might be
used to reduce the risk of reintoxication. Usually, 2 doses of
vaccine administered about 14 days apart are used.61 The
degree of protection afforded by toxoid vaccination is
Table 1. List of Botulism Vaccines
Product Name
BoNT
Type Animal Species Dosage Producer
Ultravac botulinum C
D
Cattle
Sheep
2.5 ml cattle
1.0 ml sheep
1st dose; 2nd dose after
4-6 weeks
Annual booster
Pfizer Animal Health
Longrange C
D
Cattle 2.5 ml 1st dose from 6 weeks
Annual booster
Pfizer Animal Health
Singvac 1-year
botulinum
C
D
Cattle 2.0 ml 1 dose
Annual booster
Virbac Animal Health
Singvac 3-year
botulinum
C
D
Cattle 2.0 ml 1 dose
Booster after 36
months
Virbac Animal Health
Websters LV
Bivalent botulinum
C
D
Cattle
Sheep
2.0 ml cattle
1.0 ml sheep
1st dose; 2nd dose after
4-6 weeks
Annual booster
Virbac Animal Health
Botulism Vaccine C
D
Cattle
Horses
Mules
Sheep
Goats
1.0 ml sheep and goats
2.0 ml cattle, horses,
and mules
1st dose; 2nd dose after
4-7 weeks
Annual booster
Onderstepoort Biologi-
cal Products
Botvax B B Horses 2.0 ml 3 doses at 1-month in-
tervals
Annual booster
Neogeon Corporation
Febrivac 3 plus C Mink 1.0 ml Single dose
Annual booster
Impfstoffwerk-Dessau-
Tornau Gmbh
Biocom- D C Mink 1.0 ml Single dose, Booster as
kit vaccination
United Vaccines, Inc.
Biocom –P C Mink 1.0 ml Single dose, Booster as
kit vaccination
United Vaccines, Inc.
Biocom C Mink 1.0 ml Single dose, Booster as
kit vaccination
United Vaccines, Inc.
Botumink C Mink 1.0 ml Single dose, Booster as
kit vaccination
United Vaccines, Inc.
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influenced more by the time and number of inoculations
than by the amount of toxoid injected.62
Foals can be vaccinated as early as 2 weeks of age. Their
immunization can be achieved by vaccinating pregnant
mares, considering the high titer of antibotulism antibodies
found in the colostrum. Vaccinated foals or adult horses
have to receive an annual booster.63
In the US, minks have been vaccinated against botulism
since the 1950s.64 In Europe, mink are the only animal
species routinely treated, although cattle, horses, and
pheasants are sometimes vaccinated in outbreak situations.65
Conclusion
According to EU legislation, botulism is a communicable
disease to be covered by the European epidemiologic
surveillance network, as well as a zoonosis to be monitored
according to the epidemiologic situation.62 Member states
annually report the number of human cases that have
occurred in their countries to the European Centre for
Disease Prevention and Control (ECDC) and the Euro-
pean Food Safety Agency (EFSA), but no notification
procedures are foreseen for animal disease. The lack of
compulsory notification of the disease in animals hampers
an accurate knowledge of European cases and outbreaks
and results in an underestimation of the incidence. Al-
though botulism in animals is not reported, the illness can
be classified in Europe as an emerging disease.65 The in-
crease in the number of cases of animal botulism during
the past decade is probably due to the lack of use of
antimicrobial drugs in feed and the publication of the
European Directive 2003/99/EC on the monitoring of
zoonoses and zoonotic agents.66 As a consequence of the
increased awareness by competent authorities, animal
botulism has been included in the differential diagnosis in
cases of recovery of sick or dead birds. Further efforts are
needed to reduce the underreporting of outbreaks and
improve awareness among veterinarians and other com-
petent authorities. Finally, the availability of antidotes and
vaccines to treat sick animals is essential to prevent addi-
tional cases.
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